Thymosin Alpha-1: The Immune-Modulating Peptide
Used in 30+ countries for chronic viral infection, immune dysfunction, and as a cancer adjunct. Here's what the evidence actually shows and where Valora uses it.
Thymosin alpha-1 (thymalfasin) is one of the most-studied peptides in clinical medicine globally. Approved for various immune indications in more than 30 countries — including in chronic hepatitis B, hepatitis C, and as an adjunct to cancer therapy — its U.S. use is primarily off-label, but the evidence base is substantial.
What it is
Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from the thymus gland. The thymus is where T-cells mature; thymic involution begins in adolescence and progresses throughout life, contributing to age-related immune decline.
Mechanism
TA-1 acts primarily on the innate and adaptive immune systems via Toll-like receptor 9. It enhances T-cell maturation, increases natural killer cell activity, and modulates dendritic cell function. The net effect is improved immune competence without the broad immunosuppression seen with corticosteroids.
Where the evidence is strongest
Chronic hepatitis B and C — multiple randomized trials show TA-1 improves response rates when combined with antiviral therapy. Sepsis — randomized trials in critically ill patients show improved 28-day survival in some studies. Adjunctive cancer therapy — used internationally to support immune function during chemotherapy.
Where Valora uses it
Selectively, in patients with documented chronic viral reactivation (EBV, CMV), recurrent infections suggesting immune dysregulation, or post-acute COVID syndromes with measurable immune dysfunction. We do not use it as a generic "immune booster" without a clinical reason.
Typical protocol
1.6 mg subcutaneously, twice weekly, for an initial 3-month course. Response is evaluated clinically and with appropriate immune markers. Extended courses are used in selected patients with ongoing immune dysfunction.
Safety
TA-1 has an excellent safety profile across decades of international use. Side effects are minimal — usually injection-site reactions only. It is not appropriate for patients with active organ transplantation or certain autoimmune conditions.
Sources & references
Peer-reviewed studies, clinical guidelines, and regulatory documents used to write this article.
- 1.Camerini R, Garaci E. Historical review of thymosin alpha-1 in infectious diseases. Expert Opin Biol Ther. 2015;15(Suppl 1):S117-S127.— Expert Opinion on Biological Therapy, 2015.
- 2.Wu J et al. The efficacy of thymosin alpha 1 for severe sepsis: a multicenter randomized controlled trial. Crit Care. 2013;17:R8.— Critical Care, 2013.
- 3.Garaci E et al. Thymosin alpha 1: from bench to bedside. Ann N Y Acad Sci. 2007;1112:225-234.— Annals of the New York Academy of Sciences, 2007.
How this article was written: Researched and drafted by the Valora Rx editorial team using current peer-reviewed literature and clinical practice guidelines from bodies including the Endocrine Society, AUA, NAMS, ACOG, and FDA. This article is informational and is not a substitute for individualized medical advice from your physician. Read our editorial standards →
